What to do after resistance to lorlatinib/lorlatinib

Lorlatinib/Lorlatinib (Lorlatinib) is a targeted cancer drug used to treat non-small cell lung cancer with changes in the anaplastic lymphoma kinase (ALK) gene, which is also known as ALK-positive non-small cell lung cancer. However, some patients may develop resistance to lorlatinib. If a patient is facing resistance to lorlatinib, here are some recommendations:

1. Detection of resistance mechanism: First, patients need detailed testing to determine the mechanism of resistance. This can be done through genetic testing or analysis of tissue samples. Understanding the mechanisms of resistance can help doctors choose treatment options that are more suitable for patients.

2. Seek professional advice: Communicate with doctors and consult them about treatment options after lorlatinib resistance. They may recommend switching to other targeted drugs or other treatment strategies, such as radiation therapy, chemotherapy or immunotherapy.

3. Participate in clinical trials: If existing treatment options are ineffective, patients can explore participating in relevant clinical trials. Clinical trials can provide new treatment options and opportunities, but potential risks and benefits need to be carefully evaluated.

4. Maintain an active lifestyle: In addition to treatment, it is also important to maintain an active lifestyle. A balanced diet, moderate exercise, stress reduction and good sleep have a positive impact on the body's recovery and resistance.

5. Seek social support: Facing drug resistance can be psychologically and emotionally stressful. During this process, seeking support from family, friends, or professional counselors can help patients cope with difficulties and anxieties.

Since everyone's constitution is different, their resistance to drugs is also different. If a patient develops drug resistance after taking the drug, please inform your doctor in time and do not adjust the drug dosage yourself.